Provided is the use of a composition comprising nanoparticles comprising paclitaxel and an albumin in the manufacture of a medicament for treating melanoma in a human individual, wherein the individual is selected for treatment based on the individual having: (i) a serum lactate dehydrogenase (LDH) level of >; 1.1 – 2.0 × upper limit of normal (ULN), or (ii) a melanoma comprising a mutation in BRAF.